Onconex Thyroid Cancer (Somatic)

Understanding Onconex Thyroid Cancer (Somatic)

Every year, about 12,000 men and 33,000 women get thyroid cancer, and about 950 men and 1,100 women die from the disease.

According to Surveillance, Epidemiology, and End Results (SEER) data, 89.9% of patients diagnosed with thyroid cancers have papillary thyroid carcinoma (PTC), 4.5% follicular thyroid carcinoma (FTC), 1.5% Hurthle-cell carcinoma, and 0.8% anaplastic thyroid carcinoma (ATC).

NGS offers diagnostic improvements for fine needle aspiration (FNA) cytology of thyroid with indeterminate features. It al...

What does Onconex Thyroid Cancer (Somatic) measure?

The Onconex Thyroid Cancer (Somatic) test is a comprehensive Next Generation Sequencing (NGS) assay targeting 70 genes associated with thyroid cancer, providing detailed genetic insights to guide targeted therapy and improve patient outcomes.

The Onconex Thyroid Cancer (Somatic) test offers insights into the molecular underpinnings of tumor mutation genes, facilitating the identification of novel genetic aberrations and potential therapeutic targets. As targeted therapies become the new standard of care in oncology...